Observations placeholder
Ampyra and Fampridine
Identifier
017705
Type of Spiritual Experience
Number of hallucinations: 95
Background
A description of the experience
4-Aminopyridine (4-AP, INN fampridine, USAN dalfampridine) is an organic compound with the chemical formula C5H4N–NH2. The molecule is one of the three isomeric amines of pyridine.
It is used as a research tool, in characterizing subtypes of the potassium channel. It has also been used as a drug, to manage some of the symptoms of multiple sclerosis. It was undergoing Phase III clinical trials as of 2008, and the U.S. Food and Drug Administration (FDA) approved the compound on January 22, 2010. Fampridine is also marketed as Ampyra in the United States and as Fampyra in Europe. In Canada, the medication has been approved for use by Health Canada since February 10, 2012.
On Jan, 22, 2017 32,196 people reported to have side effects when taking Ampyra. Among them, 95 people (0.3%) have Hallucination
Time on Ampyra when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 41.67% | 33.33% | 16.67% | 8.33% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Ampyra :
| Female | Male | |
| Hallucination | 89.74% | 10.26% |
Age of people who have Hallucination when taking Ampyra :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 2.63% | 0.00% | 28.95% | 68.42% |